“…Contraindications to surgical treatment and at the same time criteria for exclusion from the study were: (1) reduction in disc height > 60% at the involved level, (2) inflammation of the arachnoid membrane, (3) primary diagnosis of the cause of spinal discomfort other than DLSD in the involved segment, (4) DLSD requiring the surgical treatment of more than one level, (5) history of conservative treatment within 6 weeks before the planned surgery, (6) sequestration of herniated nucleus pulposus, (7) history of any surgery of the involved or adjacent level, (8) history of any intradiscal ablation procedure, (9) congenital or iatrogenic absence of posterior column elements (e.g., condition after resection of the intervertebral joint, spondylolysis, fracture, closed spina bifida), (10) underdevelopment or agenesis of the spinous process, (11) lower limb movement deficit, (12) cauda equina syndrome, (13) clinically significant peripheral neuropathy, ( 14) chronic ischemia of the lower extremities manifested by intermittent claudication, (15) history of traumatic fracture in L1-L5 segments, either compressive or with tearing, ( 16) lumbar scoliosis with a Cobb angle greater than 15 • , (17) established osteoporosis, osteopenia or osteomalacia, (18) obesity with a BMI of ≥40, (19) documented allergy to silicone, polyethylene, titanium or latex, (20) active bacterial infection, (21) active neoplastic disease or a history of neoplastic disease within the past 5 years including spinal neoplastic disease, (22) anesthetic contraindications to general anesthesia, and the lack of patients' informed consent.…”